Niacin/laropiprant

ApprovedSmall molecule

Merck & Co.

Niacin/laropiprant is one of 103 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Oxidative StressActive, not recruiting

HypercholesterolemiaActive, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Oxidative StressPhase 3

Active, not recruiting

HypercholesterolemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Niacin/laropiprant

1 3

Tryngolza (autoinjector)

Ionis Pharmaceuticals

Phase 3

2 4

Ziltivekimab

Novo Nordisk

Phase 3

1 5

Nitroglycerine

SShaanxi Buchang Pharmaceutical Co., Ltd

Phase 3

1 6

Repatha

Amgen

Preclinical

5 7

Mounjaro

Eli Lilly

Preclinical

1 8

Praluent

Regeneron

Preclinical

1 9

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 10

Benicar

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV-Infected Individuals1 trial

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Terminated·CCalmy Alexandra·Phase 4·NCT01683656·4 enrolled

Endothelial Function1 trial

Niacin/Laropiprant and Endothelial Function

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT01126073·60 enrolled

Oxidative Stress1 trial

The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker

Unknown status·RRambam Health Care Campus·Phase 3·NCT01071525·30 enrolled

Concentration1 trial

Effect of Niacin in the Lipoprotein (a) Concentration

Completed·IInstituto Aragones de Ciencias de la Salud·Phase 4·NCT01321034·90 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01274559·1,173 enrolled

2 more indications

Cardiovascular Disease1 trial

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Terminated·—·Phase 4·NCT01308203·32 enrolled

Hypercholesterolemia1 trial

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01294683·977 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Niacin/laropiprant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Niacin/laropiprant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Niacin/laropiprant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Niacin/laropiprant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV-Infected Individuals1 trial

Endothelial Function1 trial

Oxidative Stress1 trial

Concentration1 trial

Efficacy and Safety1 trial

Cardiovascular Disease1 trial

Hypercholesterolemia1 trial

References

Drug Info

Quick Facts

Related News